The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database

Abstract

Existing data on the prognosis and clinicopathological features of patients with metastatic renal cell carcinoma (mRCC) are limited. This study aims to investigate the prognostic value and clinicopathological features of different metastatic sites in patients with mRCC. A dataset from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database consisting of 18 registries (1973–2015) was selected for a retrospective mRCC cohort study. Information was included on the metastatic sites in lung, bone, liver, and brain. Kaplan–Meier analysis was applied to compare the survival distribution. Univariate and multivariate Cox regression models were used to analyze survival outcomes. From the SEER database, a total of 10,410 patients with primary mRCC from 2010 to 2015 were enrolled in this cohort study. Analysis indicated that 54.9%, 37.7%, 19.5%, and 10.4% of patients were found to have lung, bone, liver, and brain metastasis, respectively. There was a significantly higher risk for sarcomatoid RCC patients to develop liver metastasis as compared to patients with clear cell RCC. The median survival for patients with lung, bone, liver, or brain metastasis was 7 months, 7 months, 4 months, and 5 months, respectively. Various clinicopathological features and prognostic values are associated with different metastatic sites. Understanding these differences may enable targeted pre-treatment assessment of primary mRCC and personalized curative intervention for patients.

Proposal for a Two-Tier Re-classification of Stage IV/M1 domain of Renal Cell Carcinoma into M1 (“Oligometastatic”) and M2 (“Polymetastatic”) subdomains: Analysis of the Registry for Metastatic Renal Cell Carcinoma (REMARCC)

“…Additionally, variation in diagnostic protocols, data collection and follow-up protocols between participating centers may introduce further confounding and limitation. We acknowledge that our findings did not demonstrate location of metastasis to be associated with worsened outcomes as has been previously demonstrated in mRCC and other genitourinary malignancies which may be a result of sampling bias ( 31 – 33 ). Nonetheless, AUC demonstrated robust predictive ability comparable to existing risk stratification criteria for oncologic outcomes in metastatic RCC, and the diverse nature of this international registry and the robustness of the findings lend support to the validity and applicability of our findings.…”

A Simple-To-Use Nomogram for Predicting Early Death in Metastatic Renal Cell Carcinoma: A Population-Based Study

“…Although the treatment of mRCC has made progress in the past two decades, the prognosis of patients with mRCC remains dismal ( 15 ). Previous studies on mRCC generally concentrated on the long-term survival of patients ( 16 , 17 ) or risk factors related to lung and bone metastasis ( 18 , 19 ). However, advanced or highly invasive tumors often lead to early death and few study has identified risk factors associated with early death in mRCC.…”

Quality of Life and Role of Palliative and Supportive Care for Patients With Brain Metastases and Caregivers: A Review

“…However, while the range of neurologic and cognitive symptoms may be large among metastatic brain tumor patients, the development of BM typically portends poor overall prognosis. For example, median survival for renal cell carcinoma patients with BM was 5 months, and the median survival for patients with solid BM from non-small cell lung cancer was 8.4 months ( 7 , 8 ).…”